Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts  Rintaro Noro,

Published byHandoko Makmur Modified over 6 years ago

Similar presentations

Presentation on theme: "A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts  Rintaro Noro,"— Presentation transcript:

1 A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts  Rintaro Noro, MD, PhD, Teruhide Ishigame, MD, PhD, Naomi Walsh, PhD, MPH, Kouya Shiraishi, PhD, Ana I. Robles, PhD, Bríd M. Ryan, PhD, Aaron J. Schetter, PhD, MPH, Elise D. Bowman, MS, Judith A. Welsh, BS, Masahiro Seike, MD, PhD, Akihiko Gemma, MD, PhD, Vidar Skaug, MD, Steen Mollerup, MD, Aage Haugen, MD, Jun Yokota, MD, PhD, Takashi Kohno, PhD, Curtis C. Harris, MD  Journal of Thoracic Oncology  Volume 12, Issue 1, Pages (January 2017) DOI: /j.jtho Copyright © Terms and Conditions

2 Figure 1 Kaplan-Meier survival analysis of actinin alpha 4 gene (ACTN4) and dual specificity phosphatase 6 gene (DUSP6) expression in early-stage (stage I + II) lung squamous cell carcinoma in (A) Japan (n = 121, 5-year relapse-free survival [RFS]) and (B) National Cancer Institute–metropolitan Baltimore, Maryland, area/Norway (n = 91, 5-year cancer-specific mortality). Kaplan-Meier survival analysis of the two-gene classifier in early-stage (stage I + II) lung squamous cell carcinoma in (C) Japan (n = 121, 5-year RFS) and (D) National Cancer Institute–metropolitan Baltimore, Maryland, area (n = 91, 5-year cancer-specific mortality). Journal of Thoracic Oncology  , 65-76DOI: ( /j.jtho ) Copyright © Terms and Conditions

3 Figure 2 Kaplan-Meier survival analysis of the two-gene classifier in early-stage (stage I + II) lung squamous cell carcinoma in (A) two published cohorts with relapse-free survival (RFS) (n = 103, 5-year RFS). Forest plot of the prognostic impact of the two-gene classifier in stage I + II (B) or stage I (C) lung squamous cell carcinoma in three independent cohorts with RFS outcome. M-H, Mantel-Haenszel; CI, confidence interval. Journal of Thoracic Oncology  , 65-76DOI: ( /j.jtho ) Copyright © Terms and Conditions

4 Figure 3 Kaplan-Meier survival analysis of the two-gene classifier in early-stage (stage I + II) lung squamous cell carcinoma in (A) four published cohorts with overall survival (OS) (n = 255, 5-year OS). Forest plot of the prognostic impact of the two-gene classifier in stage I + II (B) or stage I (C) lung squamous cell carcinoma in four independent cohorts with OS outcome. M-H, Mantel-Haenszel; CI, confidence interval. Journal of Thoracic Oncology  , 65-76DOI: ( /j.jtho ) Copyright © Terms and Conditions

Download ppt "A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts  Rintaro Noro,"

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma  Yingjie.

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma  Yingjie.
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer  Ana Belén Custodio, MD, José Luis González-Larriba,

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer  Ana Belén Custodio, MD, José Luis González-Larriba,
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers  Ana I. Robles, PhD, Eri Arai,

An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers  Ana I. Robles, PhD, Eri Arai,
Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non–Small Cell Lung Cancer  Patrick Wald,

Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non–Small Cell Lung Cancer  Patrick Wald,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Similar presentations

Ads by Google